Chemoradionuclide Therapy with 186re-labeled Liposomal Doxorubicin: Toxicity, Dosimetry, and Therapeutic Response

Overview

Journal Cancer Biother Radiopharm

Specialties Oncology
Pharmacology
Radiology

Date 2011 Aug 13

PMID 21834653

Citations 10

Authors

Anuradha Soundararajan

Ande Bao

William T Phillips

Linda M McManus

Beth A Goins

Affiliations

Soon will be listed here.

Abstract

This study was performed to determine the maximum tolerated dose (MTD) and therapeutic effects of rhenium-186 ((186)Re)-labeled liposomal doxorubicin (Doxil), investigate associated toxicities, and calculate radiation absorbed dose in head and neck tumor xenografts and normal organs. Doxil and control polyethylene glycol (PEG)-liposomes were labeled using (186)Re-N,N-bis(2-mercaptoethyl)-N',N'-diethylethylenediamine (BMEDA) method. Tumor-bearing rats received either no therapy (n=6), intravenous Doxil (n=4), or escalating radioactivity of (186)Re-Doxil (185-925 MBq/kg) or (186)Re-PEG-liposomes (1110-1665 MBq/kg) and were monitored for 28 days. Based on body weight loss and systemic toxicity, MTD for (186)Re-Doxil and (186)Re-PEG-liposomes were established at injected radioactivity/body weight of 740 and 1480 MBq/kg, respectively. (186)Re-injected radioactivity/body weight for therapy studies was determined to be 555 MBq/kg for (186)Re-Doxil and 1295 MBq/kg for (186)Re-PEG-liposomes. All groups recovered from their body weight loss, leucopenia, and thrombocytopenia by 28 days postinjection. Normalized radiation absorbed dose to tumor was significantly higher for (186)Re-Doxil (0.299±0.109 Gy/MBq) compared with (186)Re-PEG-liposomes (0.096±0.120 Gy/MBq) (p<0.05). In a separate therapy study, tumor volumes were significantly smaller for (186)Re-Doxil (555 MBq/kg) compared with (186)Re-PEG-liposomes (1295 MBq/kg) (p<0.01) at 42 days postinjection. In conclusion, combination chemoradionuclide therapy with (186)Re-Doxil has promising potential, because good tumor control was achieved with limited associated toxicity.

Citing Articles

Radiation nanomedicines for cancer treatment: a scientific journey and view of the landscape.

Reilly R, Georgiou C, Brown M, Cai Z EJNMMI Radiopharm Chem. 2024; 9(1):37.

PMID: 38703297 PMC: 11069497. DOI: 10.1186/s41181-024-00266-y.

Co-Encapsulation of Simvastatin and Doxorubicin into pH-Sensitive Liposomes Enhances Antitumoral Activity in Breast Cancer Cell Lines.

Duarte J, Gomes E, de Barros A, Leite E Pharmaceutics. 2023; 15(2).

PMID: 36839690 PMC: 9960841. DOI: 10.3390/pharmaceutics15020369.

Lipidic Cubic-Phase Nanoparticles (Cubosomes) Loaded with Doxorubicin and Labeled with Lu as a Potential Tool for Combined Chemo and Internal Radiotherapy for Cancers.

Cytryniak A, Nazaruk E, Bilewicz R, Gorzynska E, Zelechowska-Matysiak K, Walczak R Nanomaterials (Basel). 2020; 10(11).

PMID: 33207760 PMC: 7696353. DOI: 10.3390/nano10112272.

Current outlook on radionuclide delivery systems: from design consideration to translation into clinics.

Peltek O, Muslimov A, Zyuzin M, Timin A J Nanobiotechnology. 2019; 17(1):90.

PMID: 31434562 PMC: 6704557. DOI: 10.1186/s12951-019-0524-9.

Nuclear imaging of liposomal drug delivery systems: A critical review of radiolabelling methods and applications in nanomedicine.

Man F, Gawne P, T M de Rosales R Adv Drug Deliv Rev. 2019; 143:134-160.

PMID: 31170428 PMC: 6866902. DOI: 10.1016/j.addr.2019.05.012.

References

Vokes E, Weichselbaum R, Lippman S, Hong W . Head and neck cancer. N Engl J Med. 1993; 328(3):184-94. DOI: 10.1056/NEJM199301213280306. View

Aytac U, Claret F, Ho L, Sato K, Ohnuma K, Mills G . Expression of CD26 and its associated dipeptidyl peptidase IV enzyme activity enhances sensitivity to doxorubicin-induced cell cycle arrest at the G(2)/M checkpoint. Cancer Res. 2001; 61(19):7204-10. View

Torchilin V . Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 2007; 9(2):E128-47. PMC: 2751402. DOI: 10.1208/aapsj0902015. View

Harrington K, Rowlinson-Busza G, Syrigos K, Vile R, Uster P, Peters A . Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model. Clin Cancer Res. 2001; 6(12):4939-49. View

Chang Y, Chang C, Chang T, Yu C, Chen L, Jan M . Biodistribution, pharmacokinetics and microSPECT/CT imaging of 188Re-bMEDA-liposome in a C26 murine colon carcinoma solid tumor animal model. Anticancer Res. 2007; 27(4B):2217-25. View

Dennington M, Carter D, Meyers A . Distant metastases in head and neck epidermoid carcinoma. Laryngoscope. 1980; 90(2):196-201. DOI: 10.1288/00005537-198002000-00002. View

Gerretsen M, Visser G, Brakenhoff R, van Walsum M, Snow G, Van Dongen G . Complete ablation of small squamous cell carcinoma xenografts with 186Re-labeled monoclonal antibody E48. Cell Biophys. 1994; 24-25:135-42. DOI: 10.1007/BF02789224. View

Zweit J . Radionuclides and carrier molecules for therapy. Phys Med Biol. 1996; 41(10):1905-14. DOI: 10.1088/0031-9155/41/10/004. View

Parkin D, Bray F, Ferlay J, Pisani P . Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001; 94(2):153-6. DOI: 10.1002/ijc.1440. View

10.

Lasic D . Novel applications of liposomes. Trends Biotechnol. 1998; 16(7):307-21. DOI: 10.1016/s0167-7799(98)01220-7. View

11.

Kievit E, van Gog F, Schluper H, Van Dongen G, Pinedo H, Boven E . Comparison of the biodistribution and the efficacy of monoclonal antibody 323/A3 labeled with either 131I or 186Re in human ovarian cancer xenografts. Int J Radiat Oncol Biol Phys. 1997; 38(4):813-23. DOI: 10.1016/s0360-3016(97)00007-2. View

12.

Gabizon A, Shmeeda H, Barenholz Y . Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003; 42(5):419-36. DOI: 10.2165/00003088-200342050-00002. View

13.

Bao A, Phillips W, Goins B, McGuff H, Zheng X, Woolley F . Setup and characterization of a human head and neck squamous cell carcinoma xenograft model in nude rats. Otolaryngol Head Neck Surg. 2006; 135(6):853-7. DOI: 10.1016/j.otohns.2006.06.1257. View

14.

Mitra A, Nan A, Line B, Ghandehari H . Nanocarriers for nuclear imaging and radiotherapy of cancer. Curr Pharm Des. 2006; 12(36):4729-49. DOI: 10.2174/138161206779026317. View

15.

Emfietzoglou D, Kostarelos K, Sgouros G . An analytic dosimetry study for the use of radionuclide-liposome conjugates in internal radiotherapy. J Nucl Med. 2001; 42(3):499-504. View

16.

Minchinton A, Tannock I . Drug penetration in solid tumours. Nat Rev Cancer. 2006; 6(8):583-92. DOI: 10.1038/nrc1893. View

17.

Milas L, Milas M, Mason K . Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol. 1999; 9(2 Suppl 1):12-26. View

18.

Stewart J . Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem. 1980; 104(1):10-4. DOI: 10.1016/0003-2697(80)90269-9. View

19.

Chatal J, Saccavini J, Gestin J, Thedrez P, Curtet C, Kremer M . Biodistribution of indium-111-labeled OC 125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian carcinomas. Cancer Res. 1989; 49(11):3087-94. View

20.

Borjesson P, Postema E, Roos J, Colnot D, Marres H, van Schie M . Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res. 2003; 9(10 Pt 2):3961S-72S. View